RenovoRx, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US75989R1077
USD
1.63
-0.07 (-4.12%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Biofrontera, Inc.
RenovoRx, Inc.
Eiger BioPharmaceuticals, Inc.
Scorpius Holdings, Inc.
Edesa Biotech, Inc.
VYNE Therapeutics, Inc.
Pasithea Therapeutics Corp.
Moleculin Biotech, Inc.
Mangoceuticals, Inc.
Eterna Therapeutics, Inc.
RVL Pharmaceuticals Plc

Why is RenovoRx, Inc. ?

1
Poor long term growth as Net Sales has grown by an annual rate of 17.87% and Operating profit at -193.17% over the last 5 years
2
Positive results in Jun 26
  • NET SALES(HY) Higher at USD 1.47 MM
  • NET PROFIT(HY) Higher at USD -6.69 MM
  • RAW MATERIAL COST(Y) Fallen by -32.22% (YoY)
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 32.52%, its profits have fallen by -14%
4
High Institutional Holdings at 31.25%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
  • The stock has generated a return of 32.52% in the last 1 year, much higher than market (S&P 500) returns of 15.76%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to RenovoRx, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is RenovoRx, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
RenovoRx, Inc.
32.52%
0.64
90.42%
S&P 500
15.76%
1.20
13.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
17.87%
EBIT Growth (5y)
-193.17%
EBIT to Interest (avg)
-10.06
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.10
Sales to Capital Employed (avg)
0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
35.53%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.13
EV to EBIT
-2.71
EV to EBITDA
-2.71
EV to Capital Employed
-16.88
EV to Sales
31.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-138.44%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company
NET SALES(HY)

Higher at USD 1.47 MM

NET PROFIT(HY)

Higher at USD -6.69 MM

RAW MATERIAL COST(Y)

Fallen by -32.22% (YoY

EPS(Q)

Highest at USD -0.06

-8What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -11.87 MM

DEBT-EQUITY RATIO (HY)

Highest at -101.23 %

PRE-TAX PROFIT(Q)

Fallen at -28.13%

NET PROFIT(Q)

Fallen at -28.13%

Here's what is working for RenovoRx, Inc.

Net Sales
At USD 1.47 MM has Grown at 137.8%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (USD MM)

Net Sales
Higher at USD 1.47 MM
than preceding 12 month period ended Jun 2026
MOJO Watch
In the half year the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

EPS
Highest at USD -0.06
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost
Fallen by -32.22% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for RenovoRx, Inc.

Operating Cash Flow
Lowest at USD -11.87 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Pre-Tax Profit
Fallen at -28.13%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Fallen at -28.13%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Debt-Equity Ratio
Highest at -101.23 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Footer loading